康柏西普眼用注射液治疗继发于病理性近视的脉络膜新生血管膜的疗效观察被引量：6

在线阅读下载PDF

导出

摘要病理性近视（pathological myopia,PM）是50岁以下人群最主要的严重致盲性眼病之一,可继发视网膜脱离、视网膜劈裂、后巩膜葡萄肿、黄斑出血、脉络膜新生血管（choroidal neovascularization,CNV）形成等眼底病变.尤其是PM性CNV是导致高度近视患者中心视力下降甚至不可逆中心视力丧失的重要原因, 大约5%~10%的高度近视患者产生黄斑区CNV[1]. PM性CNV的发病机制尚不明确,多种因素,如机械因素、遗传因素及脉络膜血液动力学因素等[2]可导致外层视网膜缺血,继而诱发CNV的产生. PM性CNV的治疗方式有多种,传统激光光凝治疗及玻璃体切除手术联合视网膜下CNV切除手术,治疗后患者视力恢复不理想,未得到广泛应用.光动力学疗法（photodynamic therapy,PDT）可以选择性地作用于CNV,阻塞新生血管以达到治疗目的,但PDT不能从根本上控制CNV的产生,治疗后复发率高. 研究已经证明血管内皮生长因子（vascular endothelial growth factor,VEGF）在PM性CNV的发生、发展中起重要作用. 而随着基础及临床研究不断开展和深入,玻璃体腔注射抗VEGF药物治疗已经成为PM性CNV热点和一线治疗方式. 康柏西普（conber-cept）是一种VEGF受体与人免疫球蛋白Fc段基因重组的融合蛋白, 可结合VEGF并竞争性抑制VEGF与受体结合,从而阻止VEGF受体激活, 抑制血管内皮细胞增殖和血管新生,达到治疗PM性CNV的目的. 本研究采用康柏西普眼用注射液玻璃体腔注射治疗PM性CNV,观察其安全性并对治疗效果进行研究.

作者师燕芸贾亚丁郑浩侯佳谢娟

机构地区山西省眼科医院眼底病科

出处《中国药物与临床》 CAS 2017年第10期1520-1522,共3页 Chinese Remedies & Clinics

关键词脉络膜新生血管膜继发视网膜脱离治疗方式病理性近视注射液疗效观察眼用 VEGF受体

分类号 R778.11 [医药卫生—眼科]

引文网络
相关文献

参考文献1

1曾苗,宋艳萍,丁琴.玻璃体腔注射康柏西普治疗病理性近视脉络膜新生血管疗效观察[J].中华眼底病杂志,2016,32(1):17-21. 被引量：38

二级参考文献15

1Krebs I,Binder S,Stolba U,et al.Choroidal neovascularization in pathologic myopia:three-year results after photodynamic therapy[J].Am J OpKtKalmol, 2005,140(3):416-425.DOI:10.1016/j.ajo.2005.03.050.
2Gharbiya M,Giustolisi R,Allievi F , et al.Choroidal neovascularization in pathologic myopia:intravitreal ranibizumab versus bevacizumab-a randomized controlled trial[J].Am J Ophthalmol,2010,149(3):458-464.DOI:10.1016/j.ajo.2009.10.010.
3Blinder KJ, Blumenkranz MS,Bressler NM,et al.Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia ,2-year results of a randomized clinical trial VIP report no.3[J].Ophthalmology,2003' HO(4):667-673.DOI:10.1016/s0161-6420(02)0l998-x.
4Neelam K,Cheung CM,Ohno-Matsui K,et al,Choroidal neovascularization in pathological myopia[J].Ophthalmology,2012,31(5):495-525.DOI:10.1016/j.preteyeres.2012.04.001.
5Lalloum F* Souied EH,Bastuji-Garin S,et al.Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia[J].Retina,2010,30(3):399-406.DOI:10.1097/IAE.0b013e3181bcef24.
6Wang F,Bai Y,Yu W,et al.Anti-angiogenic effect of KH902 on retinal neovascularization[J].Graefe7 s Arch Clin Exp Ophthalmol,2013,251(9):2131-2139.DOI:10.1007/s00417-013-2392-6.
7Li X,Xu G,Wang Y,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12- month randomized phase 2 study:AURORA study[J]. Ophthalmology,2014,121(9):1740-1747.DOI:10.1016/ j.ophtha.2014.03.026.
8Giansanti F,Virgili G,Donati MC,et al.Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia[J].Retina,2012,32(8);1547-1552. DOI:10.1097/IAE.0b013e3182411cee.
9Tatar O,Kaiserling E,Adam A,et al.Consequence of verteporfin photodynamic therapy on choroidal neovascular membranes[J].Arch Ophthalmol,2006,124(6):815-823. DOI:10.1001/archopht.124.6.815.
10Tong JP,Chan WM,Liu DT,et al.Aqueous humor levels of vascular endothelial growth factor and pigment epithelium- derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization [J].Am J Ophthalmol,2006,141(3);456-462.DOI:10.1016/j.ajo.2005.10.012.